New drug combo targets Hard-to-Treat prostate cancer
NCT ID NCT07115446
First seen Jan 08, 2026 · Last updated May 21, 2026 · Updated 29 times
Summary
This study tests two experimental drugs, HS-20093 and HRS-5041, together in men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to find the safest dose and understand side effects. About 63 participants will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.